Paradigm funds disclose significant Jade Biosciences (JBIO) ownership in Schedule 13G

Rhea-AI Filing Summary

Jade Biosciences, Inc. has a new large shareholder group reported on a Schedule 13G. Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. together report beneficial ownership of shares of Jade Biosciences common stock.

The Adviser, its general partner, and Senai Asefaw each report 3,106,793 shares of common stock, representing 5.1% of the class, with sole voting and dispositive power over those shares. Paradigm BioCapital International Fund Ltd. separately reports 2,738,259 shares, or 4.5% of the class, also with sole voting and dispositive power. Percentages are based on 60,845,967 shares of common stock outstanding as of June 5, 2026, after an equity offering. Each reporting person disclaims beneficial ownership of any shares other than those directly owned.

Key Figures

Adviser beneficial ownership: 3,106,793 shares Adviser ownership percentage: 5.1% Fund beneficial ownership: 2,738,259 shares +3 more

6 metrics

Adviser beneficial ownership 3,106,793 shares Shares of Jade Biosciences common stock reported by Adviser, Adviser GP and Senai Asefaw as of July 10, 2026

Adviser ownership percentage 5.1% Percent of Jade Biosciences common stock class held by Adviser, Adviser GP and Senai Asefaw

Fund beneficial ownership 2,738,259 shares Shares of Jade Biosciences common stock held by Paradigm BioCapital International Fund Ltd.

Fund ownership percentage 4.5% Percent of Jade Biosciences common stock class held by Paradigm BioCapital International Fund Ltd.

Shares outstanding 60,845,967 shares Jade Biosciences common stock outstanding as of June 5, 2026, after an equity offering

Date of event July 10, 2026 Date of event triggering the Schedule 13G reporting requirement

Key Terms

beneficial ownership, sole voting power, sole dispositive power, Schedule 13G, +1 more

5 terms

beneficial ownership financial

"The Fund and one or more separately managed accounts managed by the Adviser directly beneficially own the Common Stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole voting power financial

"5 | Sole Voting Power 3,106,793.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"7 | Sole Dispositive Power 3,106,793.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"The Date of Event which requires the filing of this"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

percent of class financial

"(b) | Percent of class: See Item 11 on the cover page for each Reporting Person."

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/17/2026 - 04:06 PM Accepted by SEC EDGAR 07/17/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What percentage of Jade Biosciences (JBIO) shares does Paradigm BioCapital report owning?

Paradigm BioCapital Advisors LP, its GP, and Senai Asefaw each report beneficial ownership of 3,106,793 Jade Biosciences shares, representing 5.1% of the common stock class, based on 60,845,967 shares outstanding as of June 5, 2026.

How many Jade Biosciences (JBIO) shares does Paradigm BioCapital International Fund hold?

Paradigm BioCapital International Fund Ltd. reports beneficial ownership of 2,738,259 Jade Biosciences common shares. This stake represents 4.5% of the outstanding common stock, calculated using 60,845,967 shares outstanding as of June 5, 2026.

What is the total share count used to calculate ownership percentages in the JBIO Schedule 13G?

Ownership percentages are calculated using 60,845,967 Jade Biosciences common shares outstanding as of June 5, 2026, after an equity offering, as reported in a prospectus supplement and press release issued by the company.

Who are the reporting persons in the Jade Biosciences (JBIO) Schedule 13G filing?

The reporting persons are Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., which together report beneficial ownership of Jade Biosciences common stock.

Do the Paradigm reporting persons claim full beneficial ownership of all JBIO shares mentioned?

Each reporting person states that it disclaims beneficial ownership of any Jade Biosciences common stock other than the shares directly beneficially owned by that specific reporting person, limiting their asserted economic interest accordingly.

What voting and dispositive powers do the Paradigm entities have over Jade Biosciences (JBIO) shares?

Each reporting person indicates sole voting power and sole dispositive power over its reported Jade Biosciences shares, with 0 shares subject to shared voting or shared dispositive power, as reflected in the cover-page items.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Jade Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

008064206

(CUSIP Number)

07/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 008064206

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,106,793.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,106,793.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,106,793.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 008064206

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,106,793.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,106,793.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,106,793.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): 008064206

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,106,793.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,106,793.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,106,793.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 008064206

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,738,259.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,738,259.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,738,259.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Jade Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 520 Fifth Avenue, 23rd Floor, New York, NY 10036.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP Number(s): 008064206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on July 10, 2026, the Date of Event which requires the filing of this Schedule 13G.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 60,845,967 shares of Common Stock outstanding as of June 5, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on June 4, 2026 and its Press Release issued on June 5, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	07/17/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	07/17/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	07/17/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	07/17/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement